William Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)

Written by Emily J. Thompson, Senior Investment Analyst

IKNA%

Source: Business Insider

Updated: Dec 29 2024

0mins

Source: Business Insider

Analyst Rating: William Blair analyst Matt Phipps has maintained a Buy rating on Ikena Oncology (IKNA), which closed at $1.54, with a Moderate Buy consensus and an average price target of $4.00.
Company Overview: Ikena Oncology focuses on developing innovative cancer therapies targeting specific signaling pathways, currently advancing five clinical and discovery programs.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

William Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Coinbase Reports 55% Revenue Growth to $1.9 Billion in Q3 2025, $355 Million from Stablecoins

Global X AI ETF Surges 32% in 2023, Outperforming Nasdaq

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch